- Home
- ALVR vs STCN Comparison
ALVR vs STCN Comparison
Compare ALVR & STCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- STCN
- Stock Information
- Founded
- ALVR 2013
- STCN 1986
- Country
- ALVR United States
- STCN United States
- Employees
- ALVR N/A
- STCN N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- STCN Advertising
- Sector
- ALVR Health Care
- STCN Consumer Discretionary
- Exchange
- ALVR Nasdaq
- STCN Nasdaq
- Market Cap
- ALVR 87.7M
- STCN 63.4M
- IPO Year
- ALVR 2020
- STCN 1994
- Fundamental
- Price
- ALVR $0.94
- STCN $10.40
- Analyst Decision
- ALVR Sell
- STCN
- Analyst Count
- ALVR 5
- STCN 0
- Target Price
- ALVR $1.00
- STCN N/A
- AVG Volume (30 Days)
- ALVR 155.6K
- STCN 11.9K
- Earning Date
- ALVR 11-04-2024
- STCN 12-12-2024
- Dividend Yield
- ALVR N/A
- STCN N/A
- EPS Growth
- ALVR N/A
- STCN 203.29
- EPS
- ALVR N/A
- STCN 3.17
- Revenue
- ALVR N/A
- STCN $169,044,000.00
- Revenue This Year
- ALVR N/A
- STCN N/A
- Revenue Next Year
- ALVR N/A
- STCN N/A
- P/E Ratio
- ALVR N/A
- STCN $3.19
- Revenue Growth
- ALVR N/A
- STCN N/A
- 52 Week Low
- ALVR $0.58
- STCN $7.36
- 52 Week High
- ALVR $2.49
- STCN $13.00
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- STCN 57.19
- Support Level
- ALVR $0.74
- STCN $9.90
- Resistance Level
- ALVR $0.91
- STCN $10.29
- Average True Range (ATR)
- ALVR 0.06
- STCN 0.39
- MACD
- ALVR 0.01
- STCN 0.11
- Stochastic Oscillator
- ALVR 94.50
- STCN 100.00
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.